Paragon 28 Inc

Paragon 28 — Q3 2023 Earnings Presentation

13 slides from Paragon 28's earnings presentation, Nov 7, 2023

  1. Slide 1: 3Q 2023 Update

    3Q 2023 Update November 7, 2023 Exhibit 99.2

  2. Slide 2: Forward Looking Statements

    Forward Looking Statements Except for the historical information contained herein, the matters set forth in this presentation are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to: Para

  3. Slide 3: Non-GAAP Financial Measures

    Non-GAAP Financial Measures In addition to our results and measures of performance determined in accordance with U.S. GAAP presented in this press release, we believe that certain non-GAAP financial measures are useful in evaluating and comparing our financial and operational performance over multip

  4. Slide 4: 3Q 2023 Update – Table of Contents

    3Q 2023 Update – Table of Contents 3Q 2023 and YTD Highlights 3Q 2023 and YTD Revenue Performance 2020 – 2023 YTD Operating Cash Flow Trends Ares Credit Facility: Reinforced Pathway to Cash Flow Break-even The Global Foot & Ankle Market Weighing Potential GLP-1 Impact on F&A Market Continued Strong

  5. Slide 5: 3Q 2023 and YTD Highlights

    3Q 2023 and YTD Highlights Above Market Revenue Growth and Profitability Improvements Continued in 3Q 2023; Reaffirmed 2023 Revenue Guidance Revenue Performance & Guidance Key Operational and Financial Details Strategic Highlights Global Net Revenue (YoY Growth): 3Q: $52.8M (+14.7% reported; +14.5%

  6. Slide 6: Q3 2023 and YTD Revenue Performance

    Q3 2023 and YTD Revenue Performance 3Q Net Revenue Performance Sustained performance through 3Q 2023 with significant momentum across key leading indicators to drive future growth YTD Net Revenue Performance Key KPI’s & Growth Factors Strong foundation for future growth with improvement across sever

  7. Slide 7: 2020 – 2023 YTD Operating Cash Flow Trends

    2020 – 2023 YTD Operating Cash Flow Trends Solid foundation of investments to drive P28 towards profitability and positive cash flow over time Cumulative Operating Cash Use Since Start of 2022 3Q 2023 DIOH 817 days compared to 4Q 2021 at 463 days. Inventory stockpile in 2022 and 2023 is calculated b

  8. Slide 8: Ares Credit Facility: Reinforced Pathway to Cash Flow Break-even

    “We expect continued improvements to our earnings and cash flow into 2024 and beyond, and the non-dilutive liquidity provided by Ares reinforces P28’s pathway to cash flow break-even.” – Steve Deitsch, Chief Financial Officer Ares Credit Facility: Reinforced Pathway to Cash Flow Break-even The $150M

  9. Slide 9: The Global Foot & Ankle Market

    The Global Foot & Ankle Market Global Foot & Ankle Market(1) Market Sub-segments(1) Estimated 2023 Global Market Share(2) CAGR: 7.1% Source: iData Research and Company estimates. Source: Company filings, SmartTrak, and management estimates. Fast Growing Market with Several Key Differentiators Parago

  10. Slide 10: Weighing Potential GLP-1 Impact on the F&A Market

    Weighing Potential GLP-1 Impact on the F&A Market The foot and ankle market has a unique patient population unlike any other orthopedic or med tech market We believe the foot and ankle market is well insulated from any GLP-1 headwinds and may benefit short and long-term from its use Statistics that

  11. Slide 11: Continued Strong Product Launch Cadence & Pipeline

    Continued Strong Product Launch Cadence & Pipeline 6 Product Launches and One Major Smart 28 Regulatory Milestone in 2023 YTD Robust Pipeline 20+ Active Projects in Development 2-4 Additional New Product Launches by End of 2023 Q2 Q3 and Q4 to Date April 2023: Phantom® 2nd Metatarsal Shortening Syst

  12. Slide 12: SSS

    SSS wT WY SSN WES S SSS aS = ; Zs oe ZR LOS: = —<—— —_ oS — i Ry SEZ NN il) i i i Ss

  13. Slide 13: GLP-1 Cited Sources

    GLP-1 Cited Sources Source: 2021 payor data per MedScout. Medicare Advantage included in commercial figure. Saltzman, Charles L., et al. "Epidemiology of ankle arthritis: report of a consecutive series of 639 patients from a tertiary orthopaedic center." The Iowa orthopaedic journal 25 (2005): 44. V

Paragon 28 — Q3 2023 Earnings Presentation on 6ix